Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER...

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Aggressive B-cell lymphomas in young adults (18-60 years) with intermediate prognosis require optimized treatment strategies.
• The UNFOLDER trial investigated the role of chemotherapy intensity and radiotherapy in this patient population.

Purpose of the Study:

• To evaluate the impact of R-CHOP-14 versus R-CHOP-21 chemotherapy regimens on event-free survival (EFS).
• To determine the efficacy of consolidation radiotherapy in patients with bulky or extralymphatic disease compared to observation.

Main Methods:

• Phase-3, 2x2 factorial randomized trial (UNFOLDER) involving 695 patients with aggressive B-cell lymphoma.
• Patients received either R-CHOP-14 or R-CHOP-21 chemotherapy.
• Randomization to consolidation radiotherapy or observation for eligible patients.
• Response assessment used 1999 standardized criteria, excluding FDG-PET.

Main Results:

• Consolidation radiotherapy significantly improved 3-year EFS (84% vs. 68%, P=0.0012) by reducing partial responses (2% vs. 11%).
• No significant differences were observed in progression-free survival (PFS) or overall survival (OS) between radiotherapy and observation arms.
• R-CHOP-14 and R-CHOP-21 regimens demonstrated comparable EFS, PFS, and OS.

Conclusions:

• Consolidation radiotherapy is beneficial for improving EFS in aggressive B-cell lymphoma patients with intermediate prognosis and bulky/extralymphatic disease.
• The choice between R-CHOP-14 and R-CHOP-21 does not significantly impact survival outcomes.
• Radiotherapy's benefit is linked to a reduced rate of partial responses, potentially decreasing the need for further interventions.